Menu
GWAS Study

African ancestry GWAS of dementia in a large military cohort identifies significant risk loci.

Sherva R, Zhang R, Sahelijo N et al.

36543923 PubMed ID
GWAS Study Type
22447 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SR
Sherva R
ZR
Zhang R
SN
Sahelijo N
JG
Jun G
AT
Anglin T
CC
Chanfreau C
CK
Cho K
FJ
Fonda JR
GJ
Gaziano JM
HK
Harrington KM
HY
Ho YL
KW
Kremen WS
LE
Litkowski E
LJ
Lynch J
NZ
Neale Z
RP
Roussos P
MD
Marra D
MJ
Mez J
MM
Miller MW
SD
Salat DH
TD
Tsuang D
WE
Wolf E
ZQ
Zeng Q
PM
Panizzon MS
MV
Merritt VC
FL
Farrer LA
HR
Hauger RL
LM
Logue MW
Chapter II

Abstract

Summary of the research findings

While genome wide association studies (GWASs) of Alzheimer's Disease (AD) in European (EUR) ancestry cohorts have identified approximately 83 potentially independent AD risk loci, progress in non-European populations has lagged. In this study, data from the Million Veteran Program (MVP), a biobank which includes genetic data from more than 650,000 US Veteran participants, was used to examine dementia genetics in an African descent (AFR) cohort. A GWAS of Alzheimer's disease and related dementias (ADRD), an expanded AD phenotype including dementias such as vascular and non-specific dementia that included 4012 cases and 18,435 controls age 60+ in AFR MVP participants was performed. A proxy dementia GWAS based on survey-reported parental AD or dementia (n = 4385 maternal cases, 2256 paternal cases, and 45,970 controls) was also performed. These two GWASs were meta-analyzed, and then subsequently compared and meta-analyzed with the results from a previous AFR AD GWAS from the Alzheimer's Disease Genetics Consortium (ADGC). A meta-analysis of common variants across the MVP ADRD and proxy GWASs yielded GWAS significant associations in the region of APOE (p = 2.48 × 10-101), in ROBO1 (rs11919682, p = 1.63 × 10-8), and RNA RP11-340A13.2 (rs148433063, p = 8.56 × 10-9). The MVP/ADGC meta-analysis yielded additional significant SNPs near known AD risk genes TREM2 (rs73427293, p = 2.95 × 10-9), CD2AP (rs7738720, p = 1.14 × 10-9), and ABCA7 (rs73505251, p = 3.26 × 10-10), although the peak variants observed in these genes differed from those previously reported in EUR and AFR cohorts. Of the genes in or near suggestive or genome-wide significant associated variants, nine (CDA, SH2D5, DCBLD1, EML6, GOPC, ABCA7, ROS1, TMCO4, and TREM2) were differentially expressed in the brains of AD cases and controls. This represents the largest AFR GWAS of AD and dementia, finding non-APOE GWAS-significant common SNPs associated with dementia. Increasing representation of AFR participants is an important priority in genetic studies and may lead to increased insight into AD pathophysiology and reduce health disparities.

4,012 African American cases, 18,435 African American controls

Chapter III

Study Statistics

Key metrics and study information

22447
Total Participants
GWAS
Study Type
No
Replicated
African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.